Northwire Canada EditionFriday, October 23, 2026
Northwire
⌕
SILVER 54.18 −1.5% COPPER 6.51 +1.8% OIL 103.11 +3.7% PALLADIUM 1052.75 −0.4% AGI 42.04 −0.9% GFG 0.175 +9.4% NIM 0.570 +0.0% AFM 1.29 −7.9% TI 2.65 −1.1% FEO 0.630 +3.3% MSA 8.52 +0.7% SSV 0.400 +3.2% CGD 1.35 +3.9% EQTY 0.085 +0.0% SXL 0.060 +0.0% MOG 0.455 +1.1% FCI 0.550 +0.0% GOLD 4016.10 −1.1% USA 4.40 −1.8% CUU 0.600 +3.5% SILVER 54.18 −1.5% COPPER 6.51 +1.8% OIL 103.11 +3.7% PALLADIUM 1052.75 −0.4% AGI 42.04 −0.9% GFG 0.175 +9.4% NIM 0.570 +0.0% AFM 1.29 −7.9% TI 2.65 −1.1% FEO 0.630 +3.3% MSA 8.52 +0.7% SSV 0.400 +3.2% CGD 1.35 +3.9% EQTY 0.085 +0.0% SXL 0.060 +0.0% MOG 0.455 +1.1% FCI 0.550 +0.0% GOLD 4016.10 −1.1% USA 4.40 −1.8% CUU 0.600 +3.5%
Financings

Realbotix Completes C$7,000,000 Brokered Life Offering

XBOT · Price

Executive Summary

  • Realbotix Corp. closed an upsized brokered private placement of 14,000,000 units at C$0.50 per unit, raising gross proceeds of C$7 million.
  • Each unit consists of one common share and one common‑share purchase warrant (exercise price C$0.75, exercisable through 24 Oct 2030).
  • Net proceeds will be used to advance engineering, design and commercialization of AI‑powered humanoid robots and for general corporate purposes.

Key Details

  • Offering Size & Price: 14,000,000 units @ C$0.50 per unit = C$7,000,000 gross proceeds.
  • Unit Composition: 1 common share + 1 warrant (right to purchase one additional common share at C$0.75).
  • Warrant Terms: Exercise price C$0.75; exercisable any time on or before 24 Oct 2030; subject to adjustment.
  • Agent & Placement Agents: A.G.P. Canada Investments ULC – sole bookrunner/agent; A.G.P./Alliance Global Partners – sole U.S. placement agent.
  • Commission Paid: Cash commission equal to 7.0% of the offering amount paid to the Agent.
  • Broker Warrants Issued: 980,000 non‑transferable warrants issued to the Agent (exercise price C$0.75, same expiry as unit warrants); subject to a four‑month hold period under Canadian law.
  • Use of Proceeds: Advance engineering, design and commercialization of AI‑powered humanoid robots; working capital; general corporate purposes.
  • Regulatory Framework: Offering conducted under NI 45‑106 prospectus exemptions and the Listed Issuer Financing Exemption; securities not subject to a hold period (except broker warrants).
  • U.S. Restrictions: Securities not registered in the United States and may not be offered or sold there unless an exemption is available.

Notable Quotes

  • “We are pleased to successfully complete this Offering, which provides Realbotix with the capital to achieve our objectives for the foreseeable future… With a strong balance sheet, we are confident in our ability to deploy this capital strategically to deliver strong returns on investment.” – Andrew Kiguel, Executive Chairman & CEO.
Read the original news release →

More from Realbotix Corp.